Trial Profile
Randomized, Double-Blind, Active-Controlled Study in Adults to Assess the Safety and Immunogenicity of Abbott's Candidate Quadrivalent Influenza Vaccine and its Non-Inferiority to Trivalent Influenza Vaccine
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 May 2018
Price :
$35
*
At a glance
- Drugs Influenza vaccine quadrivalent Abbott Biologicals (Primary)
- Indications Influenza virus infections
- Focus Registrational; Therapeutic Use
- Sponsors Abbott Biologicals BV
- 27 Apr 2018 Primary endpoint (Non-inferiority of QIV to TIV for immunogenicity against matched influenza strains based on post vaccination HI titres) has been met, according to results published in the Vaccine.
- 27 Apr 2018 Results (n=1980) assessing the immunogenicity and safety of subunit inactivated QIV versus TIV, were published in the Vaccine.
- 02 Mar 2016 Status changed from recruiting to completed as reported by European Clinical Trials Database record.